AI Analysis of Heart Tracings to Identify and Locate Fast Heart Rhythms
Tests an AI program that reads ECGs to diagnose fast heart rhythms.
Key facts
- Who runs it
- Inha University Hospital
- Where
- Incheon, South KoreaSee the site
- Trial code
- Registry title
- AI-Based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- 1 Dec 2023
- Expected to end
- 1 Dec 2028
- Type of study
- Observational
- Treatments tested
- AI-based ECG Diagnostic and Localization Algorithm
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain fast heart rhythm problems who had a heart rhythm study and catheter ablation, and who have usable ECG records.
- Age
- 19 years or older
- Sex
- All sexes can join
- Disease stage
- A diagnosis of one of these: paroxysmal supraventricular tachycardia (PSVT), Wolff-Parkinson-White (WPW) syndrome, premature ventricular contractions (PVC), or ventricular tachycardia (VT)
- Earlier treatment
- Must have had an electrophysiological study (EPS) and catheter ablation
- Biomarker or test result
- 12-lead ECG records that can be extracted as text (XML) files
Main reasons for not taking part
- ECG data of poor quality, as judged by the investigator
- Missing medical records needed for the study, as judged by the investigator
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age 19 years or older
- Diagnosis of one of the following arrhythmias: paroxysmal supraventricular tachycardia (PSVT), Wolff-Parkinson-White (WPW) syndrome, premature ventricular contractions (PVC), or ventricular tachycardia (VT)
- Underwent an electrophysiological study (EPS) and catheter ablation
- Available 12-lead electrocardiogram (ECG) records that can be extracted as text (XML) files
Who cannot take part
- Inadequate ECG data quality, as judged by the investigator
- Missing medical records required for the study, as judged by the investigator
Where in South Korea
- Inha University HospitalIncheon, South KoreaContact: Yongsoo Baek, MD, PhDTaking people
About the trial
What the trial wants to find out
This multicenter retrospective study aims to develop, validate, and clinically apply an artificial intelligence (AI)-powered electrocardiography (ECG) algorithm for the diagnosis and prognostic prediction of cardiovascular diseases, including coronary artery disease and heart failure. By utilizing encrypted raw 12-lead ECG text data and deep neural network models, the study evaluates the effectiveness of AI-enhanced ECG in detecting cardiac abnormalities and predicting clinical outcomes.
The group in the trial
- Cardiovascular Disease and Tachycardia Cohort
Patients aged 19 years or older diagnosed with tachycardias (including PSVT, WPW syndrome, PVC, or VT) who underwent an electrophysiological study (EPS) and radiofrequency catheter ablation (RFCA), with extractable 12-lead ECG text data\[cite: 1\].
Treatment: AI-based ECG Diagnostic and Localization Algorithm
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- AI-based Differential Diagnosis and Localization of Tachycardia Using ECG: Multicenter Registry (EP-AI ASSIST)
- Plain-language title
- AI Analysis of Heart Tracings to Identify and Locate Fast Heart RhythmsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 October 2026